Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at Jones Trading

Jones Trading started coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a research note released on Monday morning,Benzinga reports. The brokerage issued a buy rating and a $7.00 target price on the stock.

CNTX has been the subject of a number of other research reports. Guggenheim assumed coverage on shares of Context Therapeutics in a research report on Thursday, September 18th. They issued a “buy” rating and a $5.00 target price for the company. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Thursday, November 6th. Cantor Fitzgerald assumed coverage on shares of Context Therapeutics in a report on Thursday, October 2nd. They set an “overweight” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, October 8th. Finally, HC Wainwright increased their price target on Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $5.67.

Context Therapeutics Trading Down 5.5%

Context Therapeutics stock opened at $1.20 on Monday. The company has a market capitalization of $110.26 million, a price-to-earnings ratio of -5.00 and a beta of 1.94. Context Therapeutics has a 12 month low of $0.49 and a 12 month high of $1.55. The stock’s 50 day moving average is $1.16 and its 200-day moving average is $0.93.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). As a group, equities research analysts predict that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after acquiring an additional 134,449 shares during the last quarter. Citadel Advisors LLC acquired a new position in Context Therapeutics during the 3rd quarter worth approximately $100,000. Finally, Clear Harbor Asset Management LLC lifted its stake in Context Therapeutics by 60.5% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after purchasing an additional 35,000 shares during the last quarter. 14.03% of the stock is owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.